![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, March 25, 2022 5:19:27 PM
"GM-CSF is produced in large amounts under inflammatory conditions by activated cells of the immune system, and its functions on myeloid cells reflect this proinflammatory role. It is involved in the activation of myeloid cells and therefore, may be a more promising target for the development of future drugs aimed at controlling inflammatory autoimmune diseases."
This was published in the Journal of Leukocyte Biology in 2016. Interestingly, two of the compounds noted in the article are Mavrilimimab (Mavrilimumab), MedImmune's Rheumatoid Arthritis drug, and KB003, which is now known as lenzilumab.
https://jlb.onlinelibrary.wiley.com/doi/10.1189/jlb.3RU0316-144R
The National Cancer Institute defines lenzilumab as, "A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, lenzilumab binds to and neutralizes GM-CSF. This prevents GM-CSF binding to the GM-CSF receptor..." As I understand it, without this binding, the virus would be carried by myeloid cells to a receptor cell.
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lenzilumab
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM